Board of Directors.

  • Stelios Papadopoulos, Ph.D.

    Stelios Papadopoulos, Ph.D. Chair of the board, has served on our board of directors since our conversion to a corporation in January 2009 and as our Chair since June 2013, and prior to that was a director of Regulus Therapeutics LLC since July 2008. Since 1994, Dr. Papadopoulos has served as a director and, since 1998, as chair of the board for Exelixis, Inc., a publicly held biotechnology company, which he co-founded. Since July 2008, Dr. Papadopoulos has served as a member of the board of directors of Biogen Inc. (formerly Biogen Idec Inc.), a publicly held biopharmaceutical company, and has served as its chair since June 2014. Since August 2020, Dr. Papadopoulos has served as chair of the board of Eucrates Biomedical Acquisition Corp., a special purpose acquisition corporation. From 2003 to 2018, Dr. Papadopoulos served as a member of the board of directors of BG Medicine, Inc., a publicly held life sciences company. From 2000 to 2006, Dr. Papadopoulos served as Vice Chair with Cowen and Co., LLC, an investment banking firm. From 1987 to 2000, Dr. Papadopoulos served in several positions with PaineWebber, Incorporated, most recently as chair of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. Dr. Papadopoulos holds an M.S. in physics, a Ph.D. in biophysics and an MBA in finance from New York University.

  • David Baltimore, Ph.D.

    David Baltimore, Ph.D. has served on our board of directors since our conversion to a corporation in January 2009, and prior to that was a director of Regulus Therapeutics LLC since November 2007. Dr. Baltimore is currently President Emeritus and Distinguished Professor of Biology at the California Institute of Technology (“Caltech”), and before that from 1997 to 2006, Dr. Baltimore served as president of the California Institute of Technology. From 1968 to 1972, Dr. Baltimore served as an associate professor at the Massachusetts Institute of Technology, and from 1972 to 1997 was a professor at the Massachusetts Institute of Technology. From 1990 to 1994, Dr. Baltimore served as professor at The Rockefeller University where he also served as the president from July 1990 to December 1991. Dr. Baltimore served as a director of Amgen Inc., a publicly held biotechnology company from 1997 to May 2018, and also served as a director of Immune Design Corp., a publicly held biotechnology company, from 1997 until its acquisition by Merck & Co., Inc. in February 2019. In 1975, Dr. Baltimore received the Nobel Prize in Medicine as a co-recipient. Dr. Baltimore holds a Ph.D. in biology from The Rockefeller University and a B.A. from Swarthmore College.

  • Kathryn J. Collier

    Kathryn J. Collier has served on our board of directors since April 2018. Since March 2022, Ms. Collier has served as the senior vice president of corporate finance for Pattern Energy Group LP, a privately held renewable energy company. From July 2019 to March 2022, Ms. Collier served as the vice president for audit services of Sempra Energy (“Sempra”), a publicly traded energy services holding company overseeing the internal audit function for Sempra, including the Financial Leadership Program and audit oversight of Sempra’s operating companies. From March 2019 to July 2019, Ms. Collier served as the chief strategy and origination officer for Sempra LNG, a wholly-owned subsidiary of Sempra. From August 2018 to March 2019, Ms. Collier served as chief financial officer and chief administrative officer for Sempra North America Infrastructure. Ms. Collier also previously served as vice president and treasurer for Sempra from April 2012 to August 2018. Prior to joining Sempra in 2012, Ms. Collier held several executive positions within global corporate and investment banking at Bank of America Merrill Lynch. Ms. Collier holds a B.A. in accounting from Valparaiso University.

  • Jay Hagan

    Jay Hagan has served as our president and chief executive officer and principal executive officer since May 2017. Mr. Hagan previously served as our chief operating officer, principal financial officer and principal accounting officer from January 2016 to May 2017. From June 2011 through December 2015, Mr. Hagan served as the executive vice president, chief financial officer and chief business officer of Orexigen Therapeutics, Inc. (“Orexigen”). From May 2009 to June 2011, Mr. Hagan served as Orexigen’s senior vice president, corporate development, strategy and communications. From September 1998 to April 2008, Mr. Hagan served as managing director of Amgen Ventures. Prior to starting the Amgen Ventures Fund, Mr. Hagan served as head of corporate development for Amgen Inc. (“Amgen”). Before joining Amgen, Mr. Hagan spent 5 years in the bioengineering labs at Genzyme and Advanced Tissue Sciences. Mr. Hagan has served on the board of Aurinia Pharmaceuticals, Inc. since February 2018 and previously served on the board of directors of Zosano Pharma Corp, a publicly-traded biotechnology company, from May 2015 to May 2022. He received an M.B.A. from Northeastern University and a B.S. in Physiology and Neuroscience from the University of California, San Diego.

  • Alice S. Huang, Ph.D.

    Alice S. Huang, Ph.D. has served on our board of directors since January 2021. Dr. Huang is currently senior faculty associate of biology and biological engineering at Caltech, having joined Caltech in July 1997. Previous to her tenure at Caltech she was dean for science and professor of biology at New York University, professor of microbiology and molecular genetics at Harvard Medical School and director, laboratories of infectious disease at Boston Children’s Hospital. She also served as director of Virus-Host Interactions in Cancer for 15 years, a training program at Harvard funded by the National Cancer Institute. Dr. Huang has served on the Board of Trustees of the Keck Graduate Institute since 1998 and has previously served on the Board of Trustees of Waksman Foundation for Microbiology, the Rockefeller Foundation, Public Agenda, Johns Hopkins University, the Health Effects Institute, and the University of Massachusetts. Dr. Huang is serving on the advisory boards of the Institute for Basic Biomedical Sciences at Johns Hopkins University School of Medicine since 2008 as well as the Schlesinger Library at Radcliffe Institute since 2018. She has previously served on the advisory boards of the National Foundation for Infectious Diseases, the U.S. Army Medical Research and Development Command and the U.S. Food and Drug Administration. She has been a fellow of the American Association of Women in Science since 1978, American Academy of Microbiology since 1982, Academia Sinica in Taiwan since July 1990, and the American Association for the Advancement of Science since 2000, serving as its president from 2010 to 2011. Dr. Huang received her B.A., M.A. and Ph.D. degrees from the Johns Hopkins University.

  • Jake R. Nunn

    Jake R. Nunn has served on our board of directors since June 2019. Mr. Nunn is currently a venture advisor at New Enterprise Associates, Inc. (“NEA”), a venture capital firm, where he was a partner from June 2006 until January 2019. Prior to joining NEA, he served as a partner and an analyst for the MPM BioEquities Fund, a life sciences fund at MPM Capital, L.P., a private equity firm. Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments and an investment banker with Alex Brown & Sons. Mr. Nunn has served on the board of directors of Trevena, Inc., a publicly held biotechnology company focused on the central nervous system since July 2013, Addex Therapeutics Ltd., a publicly held biopharmaceutical company focused on allosteric modulators for neurological disorders since June 2018, Oventus Medical Ltd., a publicly held medical device company since February 2020 and Hexima Limited, a publicly held biopharmaceutical company focused on novel anti-fungals since September 2021. Mr. Nunn served on the board of directors of Dermira, Inc., a publicly held biopharmaceutical company focused on dermatology, from May 2011 until its acquisition by Eli Lilly and Company in February 2020. From 2009 to May 2015, Mr. Nunn served on the board of directors of Hyperion Therapeutics, Inc. and from 2008 to February 2016, Mr. Nunn served on the board of directors of TriVascular Technologies, Inc. Mr. Nunn received his A.B. in economics from Dartmouth College and his MBA from the Stanford Graduate School of Business. He also holds the Chartered Financial Analyst designation and is a member of the CFA Society of San Francisco.

  • William H. Rastetter, Ph.D.

    William H. Rastetter, Ph.D. has served on our board of directors since April 2013. From 2006 to February 2013, Dr. Rastetter served as a partner in the venture capital firm, Venrock. He served as chief executive officer of IDEC Pharmaceuticals Corp. (“IDEC Pharmaceuticals”) from December 1986 through November 2003, and as chair from May 1996 to November 2003. Upon the merger of IDEC Pharmaceuticals and Biogen Inc. in November 2003, Dr. Rastetter served as executive chair of Biogen Idec until the end of 2005. Dr. Rastetter served as chair of the board of Illumina, Inc., a publicly held biotechnology company, from 2005 to January 2016 and served on its board of directors from 1998 to January 2016. He was a founder of Receptos, Inc. in 2009 and served as its chair until the sale of the publicly held company to Celgene Corporation in 2015. Currently, he has served as the chair of the board of directors of Fate Therapeutics, Inc., a publicly held biotechnology company, since November 2011; chair of the board of directors of Neurocrine Biosciences, Inc., a publicly held biotechnology company, since May 2011 and on its board of directors since February 2010; on the board of directors of Grail, Inc., a privately-held company, since January 2016, and as its chair from August 2017 to November 2018. Dr. Rastetter served on the board of directors of Cerulean Pharma Inc. (“Cerulean”), a publicly held biotechnology company since January 2014, as its lead independent director from April 2014 to June 2016, and as its chair from June 2016 until July 2017 when Cerulean and Daré Bioscience Inc. completed a reverse merger and he currently serves as chair of the board of the surviving company, Daré Bioscience Inc., a publicly  traded company. In addition, he serves as an advisor to Illumina Ventures. He is the author of numerous scientific papers and patent applications in the fields of organic and bioorganic chemistry, protein and enzyme engineering, and biotechnology. Dr. Rastetter holds an S.B. in chemistry from the Massachusetts Institute of Technology and received his M.A. and Ph.D. in chemistry from Harvard University.

  • Hugh Rosen, M.D., Ph.D.

    Hugh Rosen, M.D., Ph.D. has served on our board of directors since June 2016. Since April 2017, Dr. Rosen has served as the president and chair of the board of Activx Biosciences, Inc., a wholly owned biopharmaceutical subsidiary of Kyorin Pharmaceutical Co., Ltd. From 2002 until March 2017, Dr. Rosen served as a professor of chemical physiology at The Scripps Research Institute (“TSRI”) in La Jolla, California where he focused on pursuing his primary interests in lymphocyte trafficking and barrier regulation by signaling lipids, and contributing towards the development of translational infrastructure at TSRI. He also served as chair of the Committee for Advanced Human Therapeutics of TSRI. Prior to joining TSRI, Dr. Rosen served in various capacities with Merck Research Laboratories most recently serving as executive director in immunology, rheumatology and infectious diseases and chair of the worldwide business strategy team for antibacterials and antifungals, reporting to the management committee. Dr. Rosen was a scientific founder of Receptos, Inc., now a wholly owned biopharmaceutical subsidiary of Celgene Corporation, and of RBNC Therapeutics, Inc. He received his M.D. from the University of Cape Town, South Africa and his Ph.D. in physiological sciences from Oxford.

  • Simos Simeonidis, Ph.D.

    Simos Simeonidis, Ph.D. has served on our board of directors since June 2019. Dr. Simeonidis has served as Portfolio Manager, Co-Chief Executive Officer & Co-Chief Investment Officer of Ally Bridge Group since July 2022. Previously, he served as a partner at Sarissa Capital from June 2017 to November 2021. Prior to joining Sarissa Capital, he was a managing director and senior biotechnology analyst at the Royal Bank of Canada in New York from July 2014 to June 2017. Dr. Simeonidis spent more than a decade covering the biotechnology sector as an analyst at a number of investment banks, including Cowen and Company, First Albany Capital and Morgan Stanley. In addition to his investment management and financial expertise, Dr. Simeonidis combines both biopharmaceutical industry and biomedical research expertise, having worked at Novartis International AG in business development and strategic planning, and prior to his corporate career, having served as a faculty member at Harvard Medical School. Dr. Simeonidis received his B.S. in biology from Loyola University Chicago, and his M.A., MPhil and Ph.D. degrees in cellular, molecular and biophysical sciences from Columbia University’s College of Physicians and Surgeons. He completed his postdoctoral fellowship at the laboratory of Professor Tucker Collins at Harvard Medical School and the Brigham and Women’s Hospital, where he worked on the transcriptional regulation of gene expression. Dr. Simeonidis also holds an MBA in healthcare management of the Wharton School of the University of Pennsylvania.

  • Pascale Witz

    Pascale Witz, MBA, MSc has served on our board of directors since June 2017. Ms. Witz is the founder and since November 2016, the president of PWH Advisors, a consultancy firm advising management at life science companies and investment firms. From September 2015 through May 2016, Ms. Witz served as the executive vice president, diabetes & cardiovascular for Sanofi, S.A. (“Sanofi”). Prior to that position, Ms. Witz served as the executive vice president, global divisions and strategic development, commencing in July 2013. During her tenure at Sanofi, she launched multiple medicines across three continents, and strengthened the pipeline through licensing and partnerships. From 2009 to 2013, Ms. Witz served as President and CEO of General Electric’s (“GE”) Pharmaceutical Diagnostics, an integrated pharmaceutical organization. Ms. Witz joined GE Healthcare in 1996, where she held various positions of increasing responsibilities and lead global businesses based out of the USA, France and the UK. She formerly worked for Becton Dickinson Pharmaceutical Systems from 1991 to 1996. Ms. Witz has served on the board of Fresenius Medical Care AG & Co. KGaA, since May 2016, Horizon Pharma, since August 2017 and PerkinElmer, Inc., since October 2017. Ms. Witz also served on the board of TESARO, Inc., from May 2018 until its acquisition by GlaxoSmithKline plc in January 2019 and from May 2016 to April 2018, served on the board of Savencia SA. Ms. Witz received her MBA from INSEAD and her M.S. in biochemistry from the Institut National des Sciences Appliquées. She was also a Ph.D. student in molecular biology at the Centre National de la Recherche Scientifique.